Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185176 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL14185179 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL14185225 | 0.89 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3594570 | 0.81 | GAA (0.54) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL14185239 | 0.81 | GAA (0.54) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL14185248 | 0.81 | GAA (0.54) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL14185172 | 0.81 | GAA (0.49) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3593551 | 0.80 | GAA (0.52) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3580492 | 0.80 | GAA (0.52) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3584855 | 0.80 | GAA (0.52) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1756080-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121116-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | TRPV1, CHRM3, TRPV3 | KDM4E 2179/4885ALDH1A1 2296/4885HPGD 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.